When Arcturus presented its mRNA vaccine candidate to Recipharm, it was at the stage of a frozen product, a ready-to-administer sterile injectable for Phase I & II clinical trials.
The inherent cryogenic logistics and storage costs associated with mRNA vaccines, as well as their intended markets created challenges for Phase III clinical trial and commercialisation.
To mitigate these challenges, Recipharm supported with the technology transfer, qualification and cGMP manufacturing of the lyophilised product to ease the complexities of distribution and extension of vaccine shelf-life.
